141 related articles for article (PubMed ID: 27862832)
1. Risk stratification: a tool to predict the course of active surveillance for localized prostate cancer?
Herden J; Heidenreich A; Weissbach L
BJU Int; 2017 Aug; 120(2):212-218. PubMed ID: 27862832
[TBL] [Abstract][Full Text] [Related]
2. Utilization of Active Surveillance and Watchful Waiting for localized prostate cancer in the daily practice.
Herden J; Weissbach L
World J Urol; 2018 Mar; 36(3):383-391. PubMed ID: 29330583
[TBL] [Abstract][Full Text] [Related]
3. Active surveillance in localized prostate cancer: comparison of incidental tumours (T1a/b) and tumours diagnosed by core needle biopsy (T1c/T2a): results from the HAROW study.
Herden J; Wille S; Weissbach L
BJU Int; 2016 Aug; 118(2):258-63. PubMed ID: 26332209
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ
BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973
[TBL] [Abstract][Full Text] [Related]
5. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
[TBL] [Abstract][Full Text] [Related]
6. Selecting men diagnosed with prostate cancer for active surveillance using a risk calculator: a prospective impact study.
van Vugt HA; Roobol MJ; van der Poel HG; van Muilekom EH; Busstra M; Kil P; Oomens EH; Leliveld A; Bangma CH; Korfage I; Steyerberg EW
BJU Int; 2012 Jul; 110(2):180-7. PubMed ID: 22112199
[TBL] [Abstract][Full Text] [Related]
7. [Patterns of care of patients with localized prostate cancer in Germany: a health care study with focus on active surveillance].
Chun FK; Becker A; Kluth LA; Seiler D; Schnell D; Fisch M; Graefen M; Weissbach L
Urologe A; 2015 Jan; 54(1):6-13. PubMed ID: 25391440
[TBL] [Abstract][Full Text] [Related]
8. Untreated Gleason Grade Progression on Serial Biopsies during Prostate Cancer Active Surveillance: Clinical Course and Pathological Outcomes.
Hussein AA; Welty CJ; Ameli N; Cowan JE; Leapman M; Porten SP; Shinohara K; Carroll PR
J Urol; 2015 Jul; 194(1):85-90. PubMed ID: 25623742
[TBL] [Abstract][Full Text] [Related]
9. Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer.
Womble PR; Montie JE; Ye Z; Linsell SM; Lane BR; Miller DC;
Eur Urol; 2015 Jan; 67(1):44-50. PubMed ID: 25159890
[TBL] [Abstract][Full Text] [Related]
10. Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer.
Loeb S; Berglund A; Stattin P
J Urol; 2013 Nov; 190(5):1742-9. PubMed ID: 23727309
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes of active surveillance for clinically localized prostate cancer in a community-based setting: results from a prospective non-interventional study.
Herden J; Schwarte A; Werner T; Behrendt U; Heidenreich A; Weissbach L
World J Urol; 2021 Jul; 39(7):2515-2523. PubMed ID: 33000341
[TBL] [Abstract][Full Text] [Related]
12. Predictors of pathologic progression on biopsy among men on active surveillance for localized prostate cancer: the value of the pattern of surveillance biopsies.
Cary KC; Cowan JE; Sanford M; Shinohara K; Perez N; Chan JM; Meng MV; Carroll PR
Eur Urol; 2014 Aug; 66(2):337-42. PubMed ID: 24035632
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Incidental Prostate Cancer by Active Surveillance: Results of the HAROW Study.
Herden J; Eminaga O; Wille S; Weissbach L
Urol Int; 2015; 95(2):209-15. PubMed ID: 26044747
[TBL] [Abstract][Full Text] [Related]
14. Active Surveillance for Incidental (cT1a/b) Prostate Cancer: Long-Term Outcomes of the Prospective Noninterventional HAROW Study.
Herden J; Schwarte A; Boedefeld EA; Weissbach L
Urol Int; 2021; 105(5-6):428-435. PubMed ID: 33517336
[TBL] [Abstract][Full Text] [Related]
15. Diffusion-weighted magnetic resonance imaging in prostate cancer patients on active surveillance one year after diagnosis and before repeat biopsy.
Vasarainen H; Lahdensuo K; Savolainen R; Ruutu M; Taari K; Rannikko A
Scand J Urol; 2013 Dec; 47(6):456-61. PubMed ID: 23327661
[TBL] [Abstract][Full Text] [Related]
16. Extended followup and risk factors for disease reclassification in a large active surveillance cohort for localized prostate cancer.
Welty CJ; Cowan JE; Nguyen H; Shinohara K; Perez N; Greene KL; Chan JM; Meng MV; Simko JP; Cooperberg MR; Carroll PR
J Urol; 2015 Mar; 193(3):807-11. PubMed ID: 25261803
[TBL] [Abstract][Full Text] [Related]
17. Risk stratification and avoiding overtreatment in localized prostate cancer.
Hanna B; Ranasinghe W; Lawrentschuk N
Curr Opin Urol; 2019 Nov; 29(6):612-619. PubMed ID: 31469662
[TBL] [Abstract][Full Text] [Related]
18. Intermediate-Term Outcomes for Men with Very Low/Low and Intermediate/High Risk Prostate Cancer Managed by Active Surveillance.
Nyame YA; Almassi N; Haywood SC; Greene DJ; Ganesan V; Dai C; Zabell J; Reichard C; Arora H; Zampini A; Crane A; Hettel D; Elshafei A; Fareed K; Stein RJ; Berglund RK; Gong M; Jones JS; Klein EA; Stephenson AJ
J Urol; 2017 Sep; 198(3):591-599. PubMed ID: 28347770
[TBL] [Abstract][Full Text] [Related]
19. Clinical characteristics and primary management of patients diagnosed with prostate cancer between 2007 and 2013: status from a Danish primary referral center.
Thomsen FB; Mikkelsen MK; Hansen RB; Krug AH; Glenthøj A; Stattin P; Brasso K
Acta Oncol; 2016 Dec; 55(12):1456-1460. PubMed ID: 27333339
[TBL] [Abstract][Full Text] [Related]
20. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression.
Choo R; Klotz L; Danjoux C; Morton GC; DeBoer G; Szumacher E; Fleshner N; Bunting P; Hruby G
J Urol; 2002 Apr; 167(4):1664-9. PubMed ID: 11912384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
